vs
Side-by-side financial comparison of Corbus Pharmaceuticals Holdings, Inc. (CRBP) and ScanTech AI Systems Inc. (STAI). Click either name above to swap in a different company.
Corbus Pharmaceuticals Holdings, Inc. is the larger business by last-quarter revenue ($1.2M vs $631.0K, roughly 1.9× ScanTech AI Systems Inc.). Corbus Pharmaceuticals Holdings, Inc. runs the higher net margin — -1159.2% vs -1532.9%, a 373.7% gap on every dollar of revenue.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel targeted therapies for rare, serious inflammatory, fibrotic and immune-mediated diseases. It primarily operates across North America and other developed markets, addressing high unmet medical needs for underserved patient populations.
CRBP vs STAI — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $631.0K |
| Net Profit | $-13.8M | $-9.7M |
| Gross Margin | — | 27.6% |
| Operating Margin | -1304.0% | -773.2% |
| Net Margin | -1159.2% | -1532.9% |
| Revenue YoY | 447.9% | — |
| Net Profit YoY | -37.1% | — |
| EPS (diluted) | $-1.15 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $631.0K | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $346.1K | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | $906.0K | — | ||
| Q1 24 | $-177.0K | — | ||
| Q4 22 | $-641.0K | — | ||
| Q3 22 | $0 | — |
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-17.9M | ||
| Q3 24 | $-13.8M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-6.9M | — | ||
| Q4 22 | $-10.9M | — | ||
| Q3 22 | $-8.8M | — |
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 29.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | — | -773.2% | ||
| Q2 25 | — | -440.1% | ||
| Q1 25 | — | -4503.9% | ||
| Q3 24 | -1304.0% | — | ||
| Q2 24 | -1212.8% | — | ||
| Q1 24 | 5436.3% | — | ||
| Q4 22 | 1684.5% | — | ||
| Q3 22 | — | — |
| Q3 25 | — | -1532.9% | ||
| Q2 25 | — | -785.1% | ||
| Q1 25 | — | -5174.2% | ||
| Q3 24 | -1159.2% | — | ||
| Q2 24 | -1103.4% | — | ||
| Q1 24 | 3897.4% | — | ||
| Q4 22 | 1697.3% | — | ||
| Q3 22 | — | — |
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.77 | ||
| Q3 24 | $-1.15 | — | ||
| Q2 24 | $-0.90 | — | ||
| Q1 24 | $-0.83 | — | ||
| Q4 22 | $-2.60 | — | ||
| Q3 22 | $-2.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.4M | — |
| Total DebtLower is stronger | — | $17.7M |
| Stockholders' EquityBook value | $150.5M | — |
| Total Assets | $164.2M | $5.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $159.4M | — | ||
| Q2 24 | $147.0M | — | ||
| Q1 24 | $120.1M | — | ||
| Q4 22 | $59.2M | — | ||
| Q3 22 | $66.2M | — |
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $17.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | $21.6M | — | ||
| Q3 22 | $21.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $150.5M | — | ||
| Q2 24 | $125.5M | — | ||
| Q1 24 | $97.0M | — | ||
| Q4 22 | $33.0M | — | ||
| Q3 22 | $41.9M | — |
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $5.1M | ||
| Q3 24 | $164.2M | — | ||
| Q2 24 | $152.0M | — | ||
| Q1 24 | $125.7M | — | ||
| Q4 22 | $66.3M | — | ||
| Q3 22 | $73.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | 0.65× | — | ||
| Q3 22 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.9M | $-758.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-758.5K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q3 24 | $-13.9M | — | ||
| Q2 24 | $-8.9M | — | ||
| Q1 24 | $-8.0M | — | ||
| Q4 22 | $-7.5M | — | ||
| Q3 22 | $-7.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-2.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | -166.0% | ||
| Q1 25 | — | -623.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | 0.0% | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
